| Roche Holding AG Basel American Depositary Shares | (OP: RHHBY) |
|
USD
|
|
Official Closing Price
/ Updated: /
|
| View: | Quote | Chart | Options | News | SEC Filings |
(RHHBY) Community Analysis from
Bulls REASONS TO BUY
|
85%
agree
7 votes
|
Genentech purchase will let the company bundle oncology products |
|
100%
agree
1 votes
|
CDC says two flu drugs, Tamiflu and Relenza, seem effective against the new strain |
|
0%
agree
0 votes
|
potential world wide pandemic |
Bears REASONS TO SELL
May 22, 2013
(Stock Blog Hub,
4/23/13)
Roche (RHHBY) recently announced that it has entered into a collaboration agreement with Ascletis to develop and commercialize Roche’s candidate danoprevir in China for treating patients...(read more)
(Stock Blog Hub,
4/18/13)
Roche Holdings Ltd. (RHHBY) recently reported results for the first quarter of 2013. Revenues grew 6% year over year to CHF 11.6 billion driven by solid demand for its cancer drugs and...(read more)
(Investment U,
3/6/13)
The following conversation took place between my wife and I a few months ago. Mrs. L: I really think you should get a flu shot this year. Me: I’ve never gotten one before and I’ve never come down with...(read more)
Roche Pharmaceuticals (RHHBY) Company Overview
There is no analysis for RHHBY yet. But you can go to Wikinvest to help create one!
What's in this RHHBY analysis on Wikinvest...
- Corporate Overview
- Recent News
- Recent Acquisitions
- Business Segments
- Pharmaceutical (78% of sales, CHF 37.06B in FY 2010)
- Cancer Drugs (57% of sales, CHF 21.3B in FY 2010)
- Other Drugs
- Diagnostics (21.9% of sales, CHF 10.4B in FY 2010)
- Research and Development (CHF 9.05B in FY 2010
- Trends and Forces
- Generic drugs: Not a large threat
- Flu Pandemics/Epidemics
- Tightening FDA Regulations
- Competition
- References
